XBIO News and Press, Xenetic Biosciences Inc. From 11/10/22

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward FR...

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XB...

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, M...

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eise...

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid t...

Biopharmaceutical firm Xenetic Biosciences ( NASDAQ: XBIO ) and VolitionRx ( NYSE: VNRX ), a developer of blood tests, have signed a research and development agreement for certain targeted cell therapies to treat cancer, the companies said on Tuesday. Xene...

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi...

Xenetic Biosciences ( NASDAQ: XBIO ) said it engaged Catalent ( NYSE: CTLT ) to manufacture the company's recombinant protein Human DNase 1 for use in a cancer study. Catalent Pharma Solutions will carry out the cGMP manufacturing of DNase to help ...

DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE / July 7, 2...

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / June 2, 2022 / JTC Team ("JTC"), a fully integrated corporate c...